team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference.
Treating multiple sclerosis (MS) in its earlier stages with Ocrevus (ocrelizumab) can substantially lower disease activity and lessen damage to the nervous system, new research demonstrates.
“We are encouraged by these new analyses showing that early treatment with Ocrevus may significantly control disease progression in both relapsing-remitting MS and in primary progressive MS,” Levi Garraway, MD, PhD, chief medical officer and head of global product development at Genentech (a member of the Roche Group), which makes Ocrevus, said in a press release.
#AANAM – Mavenclad, for RRMS, Lowers Long-term Need for Other DMTs
multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.
#AANAM - Ocrevus, Rituximab Linked to More Severe COVID-19 Cases
multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.
Gilenya is an oral treatment from Novartis that’s approved for relapsing forms of MS in people ages 10 and older. It works by retaining immune cells in lymph nodes (immune-related structures) and preventing them from reaching the brain and spinal cord, where they could cause damage to the protective myelin sheath surrounding nerve fibers.
By reducing the number of immune cells in circulation, Gilenya may reduce the immune system’s ability to fight off infectious pathogens. Yet, whether Gilenya treatment is associated with a greater risk of infections compared with other MS treatments remains controversial.
To shed light on this, researchers in China reviewed data from published clinical trials that assessed Gilenya, against a placebo or other disease-modifying therapies (DMTs), in MS patients.
team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference.
There is a lack of diversity among neurologists, who are disproportionately white men, but new programs aimed at inclusivity may help neurologists to better reflect the communities they serve.
Racial, ethnic, and gender disparities among neurologists, and strategies to address them, were discussed in several talks at this year’s virtual American Academy of Neurology Annual Meeting, which began April 17 and ends today.
Diversity among neurologists and other doctors is important for delivering optimal healthcare. Research has shown that increasing minority representation among healthcare providers can lead to better outcomes for minority patients, through factors like increased cultural competency (the ability to understand and interact with people of a particular cultural background), which is critical for bridging disparities in hea